BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-51@pharmaconomics
DTSTAMP:20260707T010011Z
DTSTART;VALUE=DATE:20261031
DTEND;VALUE=DATE:20261101
SUMMARY:CLDX Phase 3 — barzolvolimab (estimated date)
DESCRIPTION:Phase 3 trial results for barzolvolimab in Chronic Spontaneous Urticaria are due ~ Oct 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06455202\n\nTrack it: https://www.pharmaconomics.com/e/51
URL:https://www.pharmaconomics.com/e/51
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CLDX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR